PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : B

Records returned : 106 (on 21 Nov 2024 at 19:50:05).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
Bacillus calmette-guerin (B.C.G.)
No Information Returned
10.02.02
Baclofen
Spasticity and muscle spasm
Green
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
10.02.02
Baclofen
Spasticity and muscle spasm
Red
Formulations :
  • Intrathecal injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Severe chronic spasticity where oral drugs are intolerable or ineffective. Alternative to ablative neurosurgical procedures (specialist use only)
Baloxavir marboxil
No Information Returned
01.05.01
Balsalazide sodium
Inflammatory bowel disease
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Bambuterol hydrochloride
No Information Returned
10.01.03
13.05.03
Baricitinib
Paediatric indications
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
10.01.03
13.05.03
Baricitinib
Rheumatoid arthritis
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
SA
ICB
BlueTeq
NICE
Important
Severe disease only
10.01.03
13.05.03
Baricitinib
Atopic dermatitis
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
SA
ICB
BlueTeq
NICE
10.01.03
13.05.03
Baricitinib
Alopecia
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NFD1
NICE
Basiliximab
No Information Returned
Becaplermin
No Information Returned
Beclometasone dipropionate
No Information Returned
Beclometasone dipropionate (Systemic)
No Information Returned
Beclometdiprop/formoterol/glycopyrronium
No Information Returned
05.01.09
Bedaquiline
Tuberculosis
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Belatacept
No Information Returned
10.01.03
Belimumab
Systemic Lupus Erythematosus
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
10.01.03
Belimumab
Lupus nephritis
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Important
Not assessed for formulary status. NICE terminated appraisal Jul 2022
Belladonna alkaloids
No Information Returned
Bemiparin sodium
No Information Returned
02.12.00
Bempedoic acid
Lipid modification
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Only as add-on therapy for patients already on ezetimibe. Use the combination product (bempedoic acid with ezetimibe) in new patients. Specialist team initiation and supply of at least 3 months before transfer of prescribing to primary care.
Bempedoic acid/Ezetimibe
No Information Returned
02.02.01
Bendroflumethiazide
Oedema
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.02.01
Bendroflumethiazide
Hypertension
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Indapamide is the preferred diuretic treatment option. No requirement to switch from bendroflumethiazide in stable patients.
Bendroflumethiazide/potassium
No Information Returned
Benorilate
No Information Returned
Benperidol
No Information Returned
Benralizumab
No Information Returned
Benzalkonium chloride
No Information Returned
Benzatropine mesilate
No Information Returned
Benzbromarone
No Information Returned
Benznidazole
No Information Returned
Benzocaine
No Information Returned
Benzoic acid
No Information Returned
Benzoin
No Information Returned
Benzoyl peroxide
No Information Returned
Benzoyl peroxide and clindamycin phosphate
No Information Returned
Benzydamine hydrochloride
No Information Returned
Benzyl benzoate
No Information Returned
05.01.01
Benzylpenicillin sodium (Penicillin G)
Bacterial infection
Green
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Contra-indicated in Penicillin Allergy. Follow local guidelines on the use of antimicrobials.
Betacarotene
No Information Returned
04.06.00
Betahistine hydrochloride
Meniere's disease
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.06.00
Betahistine hydrochloride
Tinnitus
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Betaine anhydrous
No Information Returned
Betamethasone
No Information Returned
Betamethasone esters
No Information Returned
11.04.01
12.01.01
Betamethasone sodium phosphate
Eye inflammation
Blue
Formulations :
  • Eye drops
  • Eye ointment
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Short-term use only. Primary Care prescribing on specialist recommendation
Betamethasone valerate
No Information Returned
11.04.01
Betamethasone with neomycin
Eye inflammation and bacterial infection
Blue
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Short-term use only. Primary Care prescribing on specialist recommendation.
Betamethasone/Doxycycline/Nystatin
No Information Returned
11.06.00
Betaxolol
Glaucoma / ocular hypertension
Blue
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe generically. Initiation by specialist team before transfer of prescribing to primary care.
0.25% and 0.5% drops
11.06.00
Betaxolol
Glaucoma / ocular hypertension
Blue
Formulations :
  • Eye drops (preservative free)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe generically. Initiation by specialist team before transfer of prescribing to primary care.
0.25% preservative free drops
Betaxolol hydrochloride
No Information Returned
Bethanechol chloride
No Information Returned
08.01.05
11.08.02
Bevacizumab
Uveitis
Red
Formulations :
  • Intravitreal injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
ICB
BlueTeq
Important
2nd line option where intravitreal dexamethasone is contraindicated
08.01.05
11.08.02
Bevacizumab
Wet age-related macular degeneration
Red
Formulations :
  • Intravitreal injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
Bexarotene
No Information Returned
02.12.00
Bezafibrate
Lipid modification
Blue
Formulations :
  • Modified release tablets
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Primary care prescribing on recommendation from specialist team for Familial hypercholesterolaemia and hypertriglyceridaemia.
Bicalutamide
No Information Returned
Bictegravir/emtricitabine/tenofovir alafenamide
No Information Returned
Bifonazole
No Information Returned
03.04.01
Bilastine
Allergic rhinitis
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
11.06.00
Bimatoprost
Glaucoma / ocular hypertension
Blue
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe generically. Initiation by specialist team before transfer of prescribing to primary care
11.06.00
Bimatoprost with timolol
Glaucoma / ocular hypertension
Blue
Formulations :
  • Eye drops
  • Eye drops (preservative free, unit dose)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe generically. Initiation by specialist team before transfer of prescribing to primary care
Binimetinib
No Information Returned
Biperiden hydrochloride
No Information Returned
Biphasic insulin aspart
No Information Returned
Biphasic insulin lispro
No Information Returned
Biphasic isophane insulin
No Information Returned
01.06.02
Bisacodyl
Constipation
Green
Formulations :
  • Suppositories
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
NOTE - 7.5mg suppositories are non-formulary. Only the licensed 5mg and 10mg suppositories should be prescribed
01.06.02
Bisacodyl
Constipation
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
U
Important
7.5mg suppositories are unlicensed and not approved for use in Surrey Heartlands.
Bismuth subgallate
No Information Returned
02.04.00
Bisoprolol fumarate
Arrhythmias
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
02.04.00
Bisoprolol fumarate
Angina
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.04.00
Bisoprolol fumarate
Hypertension
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Preferred
Step 4 of the hypertension pathway. Bisoprolol / atenolol are the preferred, cardio-selective beta blockers for hypertension.
02.04.00
Bisoprolol fumarate
Heart failure
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Preferred
Bisoprolol fumarate with diuretic
No Information Returned
Bisoprolol fumarate/aspirin
No Information Returned
Bleomycin
No Information Returned
Boceprevir
No Information Returned
Boric acid
No Information Returned
Bortezomib
No Information Returned
Bosentan
No Information Returned
Bosutinib
No Information Returned
04.07.04
04.09.03
Botulinum toxin type A
Facial spasm
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Includes blepharospasm and hemifacial spasm
04.07.04
04.09.03
Botulinum toxin type A
Protective ptosis and squint
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
04.07.04
04.09.03
Botulinum toxin type A
Migraine (prevention)
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
R
NICE
Important
For Chronic migraine only
Neurology teams only
04.07.04
04.09.03
Botulinum toxin type A
Movement disorders
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Focal dystonia, dystonic torticollis, cervical dystonia, spasmodic torticollis
04.07.04
04.09.03
Botulinum toxin type A
Gastroparesis
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
RSCH - endoscopy only
04.07.04
04.09.03
Botulinum toxin type A
Pyloric spasm (post GI surgery)
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
RSCH - endoscopy only
Botulinum toxin type B
No Information Returned
01.06.05
Bowel cleansing solutions
Faecal impaction (adults)
Red
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Off-label for faecal impaction MHRA/CHM advice: Polyethylene glycol (PEG) laxatives and starch-based thickeners: potential interactive effect.
01.06.05
Bowel cleansing solutions
Faecal impaction (children)
Red
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Off-label for faecal impaction. SASH use only in paediatrics. MHRA/CHM advice: Polyethylene glycol (PEG) laxatives and starch-based thickeners: potential interactive effect.
Bran
No Information Returned
Bretylium tosilate
No Information Returned
Brigatinib
No Information Returned
Brimonidine tart (Rosacea)
No Information Returned
11.06.00
Brimonidine tartrate
Glaucoma / ocular hypertension
Blue
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe generically. Initiation by specialist team before transfer of prescribing to primary care
11.06.00
Brimonidine with timolol
Glaucoma / ocular hypertension
Blue
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe generically. Initiation by specialist team before transfer of prescribing to primary care
11.06.00
Brinzolamide
Glaucoma / ocular hypertension
Blue
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe generically. Initiation by specialist team before transfer of prescribing to primary care
Brinzolamide and timolol
No Information Returned
11.06.00
Brinzolamide with brimonidine
Glaucoma / ocular hypertension
Blue
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe generically. Initiation by specialist team before transfer of prescribing to primary care
11.06.00
Brinzolamide with timolol
Glaucoma / ocular hypertension
Blue
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe generically. Initiation by specialist team before transfer of prescribing to primary care
Brinzolamide/brimonidine
No Information Returned
04.08.01
Brivaracetam
Epilepsy
Blue
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Reserved for patients who remain uncontrolled or intolerant to all other adjuntive anti-epileptics. Only for use when levetiracetam has not been effective or tolerated.
04.08.01
Brivaracetam
Epilepsy
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Reserved for patients who remain uncontrolled or intolerant to all other adjuntive anti-epileptics. Only for use when levetiracetam has not been effective or tolerated.
13.05.03
Brodalumab (Psoriasis)
Psoriasis
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
13.05.03
Brodalumab (Psoriasis)
Psoriasis
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Bromazepam
No Information Returned
Bromfenac
No Information Returned
06.07.01
Bromocriptine
Hyperprolactinaemia
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Cabergoline should be considered 1st-line. Initiation and supply of at least one month of treatment before transfer of prescribing to primary care. Monitoring remains the responsibility pf secondary care in line with position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. https://pubmed.ncbi.nlm.nih.gov/30818417/
06.07.01
Bromocriptine
Parkinson's disease
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Important
Not a 1st-line treatment option. On-going toxicity monitoring required
06.07.01
Bromocriptine
Drug induced hyperprolactinaemia
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
06.07.01
Bromocriptine
Suppression of lactation
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Brompheniramine maleate
No Information Returned
Brompheniramine maleate combinations
No Information Returned
01.05.02
05.03.06
06.03.02
Budesonide
Inflammatory bowel disease
Green
Formulations :
  • Foam enema
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Important
Steroid safety considerations
01.05.02
05.03.06
06.03.02
Budesonide
Oesophagitis (maintenance)
Blue
Formulations :
  • Oro-dispersible
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
01.05.02
05.03.06
06.03.02
Budesonide
Nephropathy
Red
Formulations :
  • Modified release capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
Important
Not interchangeable with other budesonide preparations
01.05.02
05.03.06
06.03.02
Budesonide
Inflammatory bowel disease
Red
Formulations :
  • Modified release capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
Steroid safety considerations
3mg MR capsules - gastroenterology team only
01.05.02
05.03.06
06.03.02
Budesonide
Oesophagitis (inducing remission)
Red
Formulations :
  • Oro-dispersible
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
01.05.02
05.03.06
06.03.02
Budesonide
Inflammatory bowel disease
N/A
Formulations :
  • Suppositories
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD2
Important
Steroid safety considerations
Not assessed for formulary status. Applications for formulary entry via APC.
01.05.02
05.03.06
06.03.02
Budesonide
Covid-19
See narrative
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.02.02
Bumetanide
Oedema
Green
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.02.02
Bumetanide
Oedema
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Bumetanide/potassium
No Information Returned
Bupivacaine hydrochloride
No Information Returned
Bupivacaine hydrochloride and fentanyl citrate
No Information Returned
Buprenorph hydrochloride/naloxone hydrochloride
No Information Returned
04.07.02
Buprenorphine
Pain
Green (see narrative)
Formulations :
  • Patches
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
CD
Important
Prescribe by brand. Care: available as 3-day, 4-day and 7-day patches. Refer to Trust / Primary Care Pharmacy advice for locally preferred brands
04.07.02
Buprenorphine
Pain
Blue
Formulations :
  • Sublingual tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
CD
R
Important
Use in patients unable to tolerate oral medications or where morphine is contra-indicated
Buprenorphine hydrochloride
No Information Returned
Bupropion hydrochloride
No Information Returned
Buserelin
No Information Returned
Buspirone hydrochloride
No Information Returned
Busulfan
No Information Returned
Butobarbital
No Information Returned
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More